Organization | Nanjing Leads Biolabs Co.,Ltd

Nanjing Leads Biolabs Co.,Ltd Report issue

For profit Phase 1 Phase 2

Founded: Nanjing China (2014)

Organization Overview

First Clinical Trial

2020

NCT04640545

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Nanjing Leads Biolabs Co.,Ltd

Active Ingredients

Drugs in Phase 2 Trials (11)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

lbl-007 (3 trials)

lbl-015 (1 trial)

lbl-019 (1 trial)

lbl-024 (2 trials)

lbl-033 (1 trial)

lbl-034 (1 trial)

tislelizumab (1 trial)

toripalimab (LOQTORZ) (2 trials)

Drugs in Phase 1 Trials (1)

lbl-003 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Melanoma (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 10
# of Trial APIs: 12